Enveric Biosciences (ENVB) Fundamental Analysis: Revenue, Earnings & Valuation

1.35 / 10

Underperform

Fundamentally ENVB scores 1.4/10 (underperform). Strengths include solid accounts‑receivable turnover (31.8) and high interest coverage (65.8). Inventory turnover (53.1) is decent, but fixed‑asset turnover (1812.9) and negative income‑tax‑to‑profit ratio undermine quality, leading to a prudent outlook.

Analysis Checks(5/7)

Total operating revenue (YoY growth rate %)

Value122.16

Score2/3

Weight-12.69%

1M Return0.58%

Inventory turnover ratio

Value53.13

Score3/3

Weight13.56%

1M Return-0.67%

Accounts receivable turnover ratio

Value31.76

Score2/3

Weight13.43%

1M Return-0.65%

Income tax / Total profit (%)

Value-0.09

Score0/3

Weight30.51%

1M Return-1.54%

Fixed assets turnover ratio

Value1812.88

Score1/3

Weight25.16%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value65.76

Score2/3

Weight15.15%

1M Return-0.73%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight14.87%

1M Return-0.74%

Is ENVB undervalued or overvalued?

ENVB scores 1.35/10 on fundamentals and holds a Premium valuation at present. Backed by its -320.51% ROE, 0.00% net margin, -0.22 P/E ratio, 0.63 P/B ratio, and 84.14% earnings growth, these metrics solidify its Underperform investment rating.